Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Molecular &amp Cellular Proteomics (Impact Factor: 6.56). 12/2010; 10(3):M110.000497. DOI: 10.1074/mcp.M110.000497
Source: PubMed


Biomarkers for early detection of chronic kidney disease are needed, as millions of patients suffer from chronic diseases predisposing them to kidney failure. Protein microarrays may also hold utility in the discovery of auto-antibodies in other conditions not commonly considered auto-immune diseases. We hypothesized that proteins are released as a consequence of damage at a cellular level during end-organ damage from renal injury, not otherwise recognized as self-antigens, and an adaptive humoral immune response to these proteins might be detected in the blood, as a noninvasive tracker of this injury. The resultant antibodies (Ab) detected in the blood would serve as effective biomarkers for occult renal injury, enabling earlier clinical detection of chronic kidney disease than currently possible, because of the redundancy of the serum creatinine as a biomarker for early kidney injury. To screen for novel autoantibodies in chronic kidney disease, 24 protein microarrays were used to compare serum Ab from patients with chronic kidney disease against matched controls. From a panel of 38 antigens with increased Ab binding, four were validated in 71 individuals, with (n=50) and without (n=21) renal insufficiency. Significant elevations in the titer of novel auto-Ab were noted against angiotensinogen and PRKRIP1 in renal insufficiency. Current validation is underway to evaluate if these auto-Ab can provide means to follow the evolution of chronic kidney disease in patients with early stages of renal insufficiency, and if these rising titers of these auto-Ab correlate with the rate of progression of chronic kidney disease.

8 Reads
  • Source
    • "To validate the significant autoAbs identified by ANOVA and FitSNP analysis, we further selected autoAbs that were known to interact with antigens with biological relevance in vascular and autoimmune disease, where the autoAbs could be detected most easily by ELISA, and where ProtoArray measurements indicated a fold change of > 2 in MMD patients. Customized enzyme-linked immunosorbent assays (ELISAs) were developed as previously described [17] to detect serum immunoglobulin binding to the following array of antigens: amyloid beta A4 protein (APP), catenin, beta 1 (CTNNB1), G protein pathway suppressor 1 (GPS1), stimulated by retinoic acid 13 (STRA13), receptor tyrosine kinase-like orphan receptor 1 (ROR1), and EGF-like repeats and discoidin I-like domains 3 (EDIL3). Briefly, GST-tagged purified proteins (Invitrogen, Carlsbad, CA) were applied to a 96-well immunosorbent plate (NUNC, Rochester, NY) and incubated overnight at 4°C. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Moyamoya Disease is a rare, devastating cerebrovascular disorder characterized by stenosis/occlusion of supraclinoid internal carotid arteries and development of fragile collateral vessels. Moyamoya Disease is typically diagnosed by angiography after clinical presentation of cerebral hemorrhage or ischemia. Despite unclear etiology, previous reports suggest there may be an immunological component. Methods To explore the role of autoimmunity in moyamoya disease, we used high-density protein arrays to profile IgG autoantibodies from the sera of angiographically-diagnosed Moyamoya Disease patients and compared these to healthy controls. Protein array data analysis followed by bioinformatics analysis yielded a number of auto-antibodies which were further validated by ELISA for an independent group of MMD patients (n = 59) and control patients with other cerebrovascular diseases including carotid occlusion, carotid stenosis and arteriovenous malformation. Results We identified 165 significantly (p < 0.05) elevated autoantibodies in Moyamoya Disease, including those against CAMK2A, CD79A and EFNA3. Pathway analysis associated these autoantibodies with post-translational modification, neurological disease, inflammatory response, and DNA damage repair and maintenance. Using the novel functional interpolating single-nucleotide polymorphisms bioinformatics approach, we identified 6 Moyamoya Disease-associated autoantibodies against APP, GPS1, STRA13, CTNNB1, ROR1 and EDIL3. The expression of these 6 autoantibodies was validated by custom-designed reverse ELISAs for an independent group of Moyamoya Disease patients compared to patients with other cerebrovascular diseases. Conclusions We report the first high-throughput analysis of autoantibodies in Moyamoya Disease, the results of which may provide valuable insight into the immune-related pathology of Moyamoya Disease and may potentially advance diagnostic clinical tools.
    Orphanet Journal of Rare Diseases 03/2013; 8(1):45. DOI:10.1186/1750-1172-8-45 · 3.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomedical research is growing increasingly enamored of the promise of translational medicine. In an era of increasing costs and difficulties in the process of drug discovery, bioinformatics has taken on special importance as a tool to advance translational medicine and make it more efficient.1 Here we discuss the potential role of translational bioinformatics in addressing current and future needs, specifically in the field of transplantation with its unmet diagnostic and therapeutic needs.Clinical Pharmacology & Therapeutics (2011) 90 2, 323-327. doi:10.1038/clpt.2011.120
    Clinical Pharmacology &#38 Therapeutics 06/2011; 90(2):323-7. DOI:10.1038/clpt.2011.120 · 7.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic allograft injury (CAI) results from a humoral response to mismatches in immunogenic epitopes between the donor and recipient. Although alloantibodies against HLA antigens contribute to the pathogenesis of CAI, alloantibodies against non-HLA antigens likely contribute as well. Here, we used high-density protein arrays to identify non-HLA antibodies in CAI and subsequently validated a subset in a cohort of 172 serum samples collected serially post-transplantation. There were 38 de novo non-HLA antibodies that significantly associated with the development of CAI (P<0.01) on protocol post-transplant biopsies, with enrichment of their corresponding antigens in the renal cortex. Baseline levels of preformed antibodies to MIG (also called CXCL9), ITAC (also called CXCL11), IFN-γ, and glial-derived neurotrophic factor positively correlated with histologic injury at 24 months. Measuring levels of these four antibodies could help clinicians predict the development of CAI with >80% sensitivity and 100% specificity. In conclusion, pretransplant serum levels of a defined panel of alloantibodies targeting non-HLA immunogenic antigens associate with histologic CAI in the post-transplant period. Validation in a larger, prospective transplant cohort may lead to a noninvasive method to predict and monitor for CAI.
    Journal of the American Society of Nephrology 02/2012; 23(4):750-63. DOI:10.1681/ASN.2011060596 · 9.34 Impact Factor
Show more